Loading...

Universal Biosensors

ASX:UBI
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UBI
ASX
A$39M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a medical diagnostics company in Australia. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
UBI Share Price and Events
7 Day Returns
4.8%
ASX:UBI
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-15.4%
ASX:UBI
-3.3%
AU Medical Equipment
4.9%
AU Market
UBI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Universal Biosensors (UBI) 4.8% 8.6% 0% -15.4% -18.5% -42.1%
AU Medical Equipment 4.1% -0.5% 1.1% -3.3% 38.7% 103.7%
AU Market -0% 1% 6.3% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • UBI underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • UBI underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
UBI
Industry
5yr Volatility vs Market

Value

 Is Universal Biosensors undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Universal Biosensors. This is due to cash flow or dividend data being unavailable. The share price is A$0.22.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Universal Biosensors's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Universal Biosensors's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:UBI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.21
ASX:UBI Share Price ** ASX (2019-04-18) in AUD A$0.22
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Universal Biosensors.

ASX:UBI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:UBI Share Price ÷ EPS (both in AUD)

= 0.22 ÷ 0.21

1.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Universal Biosensors is good value based on earnings compared to the AU Medical Equipment industry average.
  • Universal Biosensors is good value based on earnings compared to the Australia market.
Price based on expected Growth
Does Universal Biosensors's expected growth come at a high price?
Raw Data
ASX:UBI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Universal Biosensors, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Universal Biosensors's assets?
Raw Data
ASX:UBI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.29
ASX:UBI Share Price * ASX (2019-04-18) in AUD A$0.22
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:UBI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:UBI Share Price ÷ Book Value per Share (both in AUD)

= 0.22 ÷ 0.29

0.77x

* Primary Listing of Universal Biosensors.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Universal Biosensors is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Universal Biosensors's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Universal Biosensors has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Universal Biosensors expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universal Biosensors has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Universal Biosensors expected to grow at an attractive rate?
  • Unable to compare Universal Biosensors's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Universal Biosensors's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Universal Biosensors's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:UBI Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:UBI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:UBI Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 69 2 38
2018-09-30 65 7 39
2018-06-30 24 8 -4
2018-03-31 25 9 -3
2017-12-31 25 9 -1
2017-09-30 26 1 6
2017-06-30 23 9 5
2017-03-31 22 8 5
2016-12-31 19 7 1
2016-09-30 17 6 -6
2016-06-30 20 3 -4
2016-03-31 19 -2 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Universal Biosensors is high growth as no earnings estimate data is available.
  • Unable to determine if Universal Biosensors is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:UBI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Universal Biosensors Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:UBI Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.21
2018-09-30 0.22
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 0.00
2017-09-30 0.03
2017-06-30 0.03
2017-03-31 0.03
2016-12-31 0.01
2016-09-30 -0.04
2016-06-30 -0.02
2016-03-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Universal Biosensors will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Universal Biosensors is trading at Universal Biosensors'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Universal Biosensors's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Universal Biosensors's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Universal Biosensors's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Universal Biosensors has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Universal Biosensors performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Universal Biosensors's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Universal Biosensors has delivered over 20% year on year earnings growth in the past 5 years.
  • Universal Biosensors has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Universal Biosensors has become profitable in the last year making it difficult to compare the AU Medical Equipment industry average.
Earnings and Revenue History
Universal Biosensors's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Universal Biosensors Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:UBI Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 69.46 37.56 7.22 11.58
2018-09-30 65.24 39.31 7.22 12.66
2018-06-30 24.35 -3.74 7.68 13.09
2018-03-31 24.94 -3.05 7.40 12.64
2017-12-31 25.19 -0.76 7.29 10.83
2017-09-30 25.72 5.92 7.20 10.94
2017-06-30 22.66 4.94 6.84 11.03
2017-03-31 21.67 5.27 6.25 10.70
2016-12-31 18.83 1.25 6.29 12.68
2016-09-30 17.10 -5.64 6.50 13.60
2016-06-30 19.81 -3.64 6.55 15.31
2016-03-31 18.76 -5.36 6.84 18.22
2015-12-31 16.77 -6.58 6.54 16.77
2015-09-30 18.04 -4.76 5.69 18.12
2015-06-30 14.12 -6.49 5.68 17.85
2015-03-31 11.29 -8.59 5.86 17.16
2014-12-31 9.53 -9.32 6.14 16.62
2014-09-30 7.95 -12.11 6.31 17.58
2014-06-30 8.38 -10.90 6.47 16.76
2014-03-31 11.63 -10.59 6.28 15.94
2013-12-31 15.09 -11.63 6.20 15.48
2013-09-30 18.36 -12.76 6.60 16.14
2013-06-30 24.51 -13.40 6.52 16.00
2013-03-31 28.05 -11.37 6.61 15.68
2012-12-31 29.65 -9.13 6.79 13.48
2012-09-30 29.29 -8.12 6.71 11.93
2012-06-30 23.11 -10.15 7.13 10.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Universal Biosensors made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Universal Biosensors used its assets more efficiently than the AU Medical Equipment industry average last year based on Return on Assets.
  • Universal Biosensors has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Universal Biosensors's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Universal Biosensors has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Universal Biosensors's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Universal Biosensors's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Universal Biosensors is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Universal Biosensors's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Universal Biosensors's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Universal Biosensors has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Universal Biosensors Company Filings, last reported 3 months ago.

ASX:UBI Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 50.67 0.00 11.80
2018-09-30 54.35 20.66 28.53
2018-06-30 12.47 20.15 27.90
2018-03-31 12.96 19.40 25.28
2017-12-31 12.77 19.03 26.26
2017-09-30 14.92 18.92 19.83
2017-06-30 15.95 19.29 19.96
2017-03-31 15.69 19.48 17.78
2016-12-31 13.25 20.66 20.40
2016-09-30 8.43 19.19 21.64
2016-06-30 10.36 19.77 13.22
2016-03-31 11.61 19.23 11.33
2015-12-31 13.26 20.19 14.35
2015-09-30 15.41 20.65 17.35
2015-06-30 15.59 18.90 10.72
2015-03-31 16.89 19.15 14.81
2014-12-31 19.74 18.00 16.33
2014-09-30 20.62 16.35 19.83
2014-06-30 22.45 15.32 15.87
2014-03-31 25.89 15.76 19.46
2013-12-31 29.68 15.86 23.74
2013-09-30 31.67 0.13 14.67
2013-06-30 32.16 0.38 18.10
2013-03-31 34.91 0.58 20.23
2012-12-31 39.37 0.00 23.65
2012-09-30 30.95 0.15 13.94
2012-06-30 32.02 0.38 14.71
  • Universal Biosensors has no debt.
  • Universal Biosensors has no debt compared to 5 years ago when it was 53.5%.
  • Universal Biosensors has no debt, it does not need to be covered by operating cash flow.
  • Universal Biosensors has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Universal Biosensors's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Universal Biosensors has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Universal Biosensors's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Universal Biosensors dividends.
If you bought A$2,000 of Universal Biosensors shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Universal Biosensors's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Universal Biosensors's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:UBI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Universal Biosensors has not reported any payouts.
  • Unable to verify if Universal Biosensors's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Universal Biosensors's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Universal Biosensors has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Universal Biosensors's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Universal Biosensors afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Universal Biosensors has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Universal Biosensors's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Legleiter
COMPENSATION A$1,222,768
AGE 58
TENURE AS CEO 1.5 years
CEO Bio

Mr. Rick Legleiter, B.S., M.B.A. has been the Chief Executive Officer at Universal Biosensors, Inc., since October 01, 2017. Mr. Legleiter has 16 years of international healthcare and medical technology experience spanning Europe, Australia, Asia including China and the U.S.A. His career has comprised extensive global management, strategy, business development and customer service responsibilities, including within UBI's market segment. He has held senior roles at Siemens Healthcare in America and Germany for 14 years, over the period 2003 to 2016. Mr. Legleiter served as Senior Vice President, Healthcare Account Management, where he established and led the key account management sales function for the full laboratory and point-of-care diagnostics and imaging product portfolio. Other senior roles held by Mr. Legleiter at Siemens Healthcare include: Senior Vice President, Global Account Management, Laboratory Diagnostics Division; Senior Vice President, Customer Service, U.S.A.; and Vice President, Worldwide Customer Service, Molecular Imaging / Nuclear Medicine Business Unit. In addition, Mr. Legleiter has notable project management expertise in post-merger integration and business improvement programs. His earlier work experiences include Deloitte Consulting, Mazda Motor and Daimler in both advisory and customer service roles. Mr. Legleiter has been Member of the Service Executive Industry Board at ServiceSource Corporation (now known as ServiceSource International, Inc.) since December 2009. Mr. Legleiter holds a Master of Business Administration from Harvard Business School in 1988, Bachelor of Science in Nuclear Engineering from Kansas State University in 1982 and Bachelor of Science in Applied Mathematics from Kansas State University in 1981.

CEO Compensation
  • Insufficient data for Rick to compare compensation growth.
  • Rick's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Universal Biosensors management team in years:

2.8
Average Tenure
58
Average Age
  • The tenure for the Universal Biosensors management team is about average.
Management Team

Rick Legleiter

TITLE
Chief Executive Officer
COMPENSATION
A$1M
AGE
58
TENURE
1.5 yrs

Salesh Balak

TITLE
CFO & Company Secretary
COMPENSATION
A$418K
AGE
49
TENURE
12.4 yrs

Judy Andrews

TITLE
Director of Operations & Manufacturing Engineering
TENURE
0.8 yrs

Irene Wong

TITLE
HR Director
TENURE
2.8 yrs

Ron Chatelier

TITLE
Chief Research Scientist
COMPENSATION
A$113K
AGE
58
TENURE
17 yrs
Board of Directors Tenure

Average tenure and age of the Universal Biosensors board of directors in years:

3.6
Average Tenure
59.5
Average Age
  • The tenure for the Universal Biosensors board of directors is about average.
Board of Directors

Craig Coleman

TITLE
Non-Executive Chairman
COMPENSATION
A$110K
AGE
53
TENURE
1.7 yrs

Judith Smith

TITLE
Independent Non-Executive Director
COMPENSATION
A$64K
AGE
62
TENURE
4.1 yrs

Marshall Heinberg

TITLE
Independent Non-Executive Director
COMPENSATION
A$57K
AGE
61
TENURE
9.3 yrs

David Hoey

TITLE
Independent Non-Executive Director
COMPENSATION
A$59K
AGE
58
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
31. Mar 19 Buy Jencay Capital Pty Ltd Company 05. Jan 19 26. Mar 19 1,850,453 A$0.22 A$399,357
06. Mar 19 Buy CVC Limited Company 05. Mar 19 05. Mar 19 176,151 A$0.30 A$52,295
06. Mar 19 Buy Viburnum Funds Pty Ltd. Company 08. May 18 08. May 18 4,580 A$0.32 A$1,449
05. Mar 19 Buy CVC Limited Company 01. Mar 19 01. Mar 19 100,000 A$0.30 A$29,633
08. Jan 19 Buy Jencay Capital Pty Ltd Company 29. Nov 18 04. Jan 19 1,864,065 A$0.23 A$431,795
06. Dec 18 Buy CVC Limited Company 04. Dec 18 04. Dec 18 1,500,000 A$0.29 A$428,148
03. Dec 18 Buy Jencay Capital Pty Ltd Company 16. Jun 18 28. Nov 18 2,237,298 A$0.24 A$535,113
05. Nov 18 Buy CVC Limited Company 11. Oct 18 11. Oct 18 100,000 A$0.32 A$32,366
10. Oct 18 Buy CVC Limited Company 02. Oct 18 10. Oct 18 5,292,650 A$0.22 A$1,180,528
28. Sep 18 Buy CVC Limited Company 04. Sep 18 27. Sep 18 2,695,534 A$0.25 A$673,311
30. Aug 18 Buy CVC Limited Company 24. Jul 18 28. Aug 18 2,004,466 A$0.26 A$514,245
23. Jul 18 Buy CVC Limited Company 30. May 18 19. Jul 18 2,032,555 A$0.25 A$511,216
18. Jun 18 Buy Jencay Capital Pty Ltd Company 02. May 18 15. Jun 18 1,946,372 A$0.24 A$471,832
25. May 18 Buy CVC Limited Company 25. Jan 18 25. May 18 3,745,410 A$0.25 A$929,959
11. May 18 Buy Viburnum Funds Pty Ltd. Company 09. May 18 09. May 18 66,584 A$0.32 A$21,426
07. May 18 Buy Jencay Capital Pty Ltd Company 01. Jan 18 01. May 18 279,703 A$0.25 A$69,317
09. May 18 Buy Rick Legleiter Individual 04. May 18 04. May 18 158,687 A$0.34 A$54,545
07. May 18 Buy Viburnum Funds Pty Ltd. Company 03. May 18 07. May 18 322,945 A$0.31 A$98,949
X
Management checks
We assess Universal Biosensors's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Universal Biosensors has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Should Investors Know About Universal Biosensors Inc's (ASX:UBI) Capital Returns?

and want to begin learning the link between Universal Biosensors Inc (ASX:UBI)’s return fundamentals and stock market performance. … You need to pay attention to this because your return on investment is linked to dividends and internal investments to improve the business, which can only occur if the company is expected to produce adequate earnings with the capital that has been provided. … To understand Universal Biosensors’s capital returns we will look at a useful metric called return on capital employed.

Simply Wall St -

Universal Biosensors Inc (ASX:UBI): Time For A Financial Health Check

While small-cap stocks, such as Universal Biosensors Inc (ASX:UBI) with its market cap of AU$41.48m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Should You Be Concerned About Universal Biosensors Inc's (ASX:UBI) Investors?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Private Company Ownership Potential investors in UBI should also look at another important group of investors: private companies, with a stake of 10.18%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: A relatively significant holding of company insiders could mean high alignment with shareholders.

Simply Wall St -

How Does Investing In Universal Biosensors Inc (ASX:UBI) Impact Your Portfolio?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect UBI to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.

Simply Wall St -

What You Must Know About Universal Biosensors Inc's (ASX:UBI) Financial Strength

Moreover, UBI has produced cash from operations of AU$8.69M in the last twelve months, leading to an operating cash to total debt ratio of 45.67%, signalling that UBI’s debt is appropriately covered by operating cash. … In UBI’s case, it is able to generate 0.46x cash from its debt capital. … Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.Next Steps: UBI’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Universal Biosensors Inc (ASX:UBI): Time For A Financial Health Check

On top of this, UBI has generated cash from operations of A$7.0M over the same time period, leading to an operating cash to total debt ratio of 0.34x, indicating that UBI’s current level of operating cash is not high enough to cover debt. … At the current liabilities level of A$5.9M liabilities, the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 5.93x. … ASX:UBI Historical Debt Dec 4th 17 Is UBI’s level of debt at an acceptable level?

Simply Wall St -

Breaking Down Universal Biosensors Inc's (ASX:UBI) Ownership Structure

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in UBI should also look at another important group of investors: private companies, with a stake of 16.00%, who are primarily invested because of strategic and capital gain interests. … With a low level of institutional ownership, investors in UBI need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Company Info

Description

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a medical diagnostics company in Australia. It focuses on the research, development, and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. The company uses electrochemical cell technology platform to develop point-of-care testing systems for various markets. Its products and services include prothrombin time international normalized ratio coagulation test strips; and blood glucose monitoring supplies. Universal Biosensors, Inc. has collaboration agreement with Siemens Healthcare Diagnostics Inc. to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. The company was founded in 2001 and is based in Rowville, Australia.

Details
Name: Universal Biosensors, Inc.
UBI
Exchange: ASX
Founded: 2001
A$39,044,174
177,473,520
Website: http://www.universalbiosensors.com
Address: Universal Biosensors, Inc.
1 Corporate Avenue,
Rowville,
Victoria, 3178,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX UBI NPV (CDI) Australian Securities Exchange AU AUD 13. Dec 2006
CHIA UBI NPV (CDI) Chi-X Australia AU AUD 13. Dec 2006
Number of employees
Current staff
Staff numbers
67
Universal Biosensors employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 10:33
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.